Only One in Five Young Adults Adhere After First Psychosis
This large claims analysis quantifies just how poor antipsychotic adherence is in commercially insured first-episode psychosis and links it to acute care use, giving psychiatric pharmacists concrete targets for early intervention.
📅 Journal publication: Sep 1, 2026·Last updated: Oct 6, 2026
antipsychoticslong-acting injectablesfirst-episode psychosisschizophreniamedication adherenceproportion of days coveredhealth care utilizationclaims analysisretrospective cohortpsychiatryPsychiatry / Psychopharmacology
Background Information
First-episode psychosis patients show alarmingly low antipsychotic adherence.
Understanding medication adherence in early psychosis is crucial for improving long-term outcomes and reducing health care burdens. Only 19.1% of individuals adhered to antipsychotics, with better adherence linked to fewer emergency department (ED) visits. Low adherence to antipsychotics among first-episode psychosis patients underscores the need for targeted interventions to enhance medication compliance and improve treatment outcomes. Improving antipsychotic adherence in first-episode psychosis could reduce ED visits and improve overall outcomes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Chi E, Sridhar S, Montesano V, Ramos J, Breitborde NJK, Seiber EE
Citation:Chi E, Sridhar S, Montesano V, et al. Treatment Adherence and Health Care Utilization After a First Episode of Psychosis. JAMA network open. 2026;9(9):e2635805. doi:10.1001/jamanetworkopen.2026.35805